UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal

Brokerage UBS raises PT on biotech firm Blueprint Medicines Corp BPMC.O to $129 from $88; setting it in line with Sanofi's buyout price for the co

Maintains "neutral" rating

French drugmaker Sanofi SASY.PA said on Monday it has agreed to buy BPMC for up to $9.5 billion to boost its position in rare immunology diseases

UBS sees limited or no overlap in both companies' portfolios

Sanofi gains Ayvakit to treat a type of rare immunology disease called advanced and indolent systemic mastocytosis with $478.9 million revenue in 2024 - UBS

Including session's moves, stock up 46.9% YTD